期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

改变乳腺癌临床实践的重要临床试验的回顾与评述 被引量：22

Review and evaluation for the key clinical trials that may change clinical practice of breast cancer
在线阅读 下载PDF
导出
摘要 近20年来,开展了一系列乳腺癌辅助治疗临床试验,其中一些重要临床试验改变了乳腺癌的临床实践,从而使乳腺癌从单一手术治疗模式过渡到今天被广泛接受的综合治疗模式。本文就这些重要临床试验作一介绍和评述。 A lot of clinical trials of adjuvant treatment in breast cancer have been done, among which, a number of key clinical trails have changed our clinical practice, this has lead to multi-modality treatment instead of operation alone in breast cancer treatment. These key clinical trails were reviewed and evaluated in this article.
作者 徐兵河
机构地区 中国医学科学院中国协和医科大学附属肿瘤医院肿瘤研究所内科
出处 《中国癌症杂志》 CAS CSCD 2005年第5期408-412,共5页 China Oncology
关键词 乳腺肿瘤 辅助治疗 临床试验 临床实践 breast neoplasm adjuvant therapy clinical trail clinical pracitice
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Bonadonna G, Brusamolion E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer[ J]. N Engl J Med, 1976,294( 8 ) :405-410.
  • 2Bonadonna G, Valagussa PM,Olitemi A, et al. Adjuvant cyclophoshamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up [ J ]. N Engl J Med, 1995,332 ( 14 ) :901-906.
  • 3Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study [ J ]. Br Med J, 2005,330 ( 7485 ): 217 -220.
  • 4Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 [ J ]. J Clin Oncol,1990,8 ( 9 ): 1483-1496.
  • 5Early Breast Cancer Trialist' s Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials [ J ]. Lancet, 1998,352 ( 9132 ) :930-932.
  • 6Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patients and a natural history follow-up study in low risk node negative patients: first results of Intergroup trial in 0102 [ J ]. Proc Am Soc Clin Oncol , 1998,17: Abst 2.
  • 7Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[ J]. J Clin Oncol,2003,21(6) :976-983.
  • 8Mamounas EP, Bryant J, Lembersky BC, et al. paclitaxel (T)following doxorubicin/cyclophosphamide ( AC ) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 [ J ]. Proc Am Soc Clin Oncol,2003,22:12A ( Abstr12).
  • 9Nabholtz JM,Pienkowski T, Mackey J, et al. Phase Ⅲ trial comparing TAC (docetaxel, doxorubicin, cyclophsphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer ( BC ) patients:interim analysis of the BCIRG 001 study[J]. Proc Am Soc Clin Oncol,2002,21:36a ( Abstr 141 ).
  • 10Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer; first report of intergroup trail C9741/Cancer and leukemia Group B trial 9741[ J]. J Clin Onco1,2003,21 ( 8 ) :1431-1439.

同被引文献199

引证文献22

二级引证文献124

中国癌症杂志
2005年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部